NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
Scientists Just Discovered a Surprising Health Risk of a High-Protein Diet
Reviewed by Dietitian Emily Lachtrupp, M.S., RD Design elements: Getty Images. EatingWell design. Key Points A new study…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…